Please login to the form below
Shock as NICE turns down Biogen’s SMA therapy
UK’s cost effectiveness watchdog says the drug’s long-term benefits are unclear
FDA gives breakthrough status to Xolair for food allergies
Food allergies could open up big new market for biologic
Confidence in UK’s post-Brexit healthcare sector on the wane
Only 37% of healthcare workers agree that the UK would be an attractive destination after EU departure
Promising more appraisal capacity, NICE revives industry fee idea
Rising workload and shrinking budget making charges inevitable
Can a post-Brexit UK stay aligned with Europe on clinical research?
There's still no guarantee the UK can keep in step with EU
FDA clears Kyowa Kirin’s skin lymphoma therapy Poteligeo
Becomes the first drug approved to treat Sézary syndrome
Pharma survey: No Brexit is the best option
But many believe a 'no deal' Brexit most likely outcome
UK unveils plans for bigger medicines price squeeze
Company payments to government would rise steeply to 2021
As ‘No Deal’ fears grow, pharma can’t rely on transition period
UK could still remain part of EMA 'club' until 2020 - but time is running out
Moving times
Continuity and stability are vital when it comes to the EMA's relocation when it leaves London
-
SMC gives green light for Amgen’s KyprolisThe committee also gives verdict on three other products
-
Facing the new wave of biosimilarsDon’t drown out the patient voice, says advocacy group
-
Ionis and Roche gain PRIME status for Huntingdon’s disease candidateMore good news for Ionis after first drug approval
-
Daiichi gets breakthrough status for pre-NDA leukaemia drugQuizartinib could have an advantage over rival drug Rydapt
-
EMA cuts back as Brexit staff losses top expectationsRegulator says it faces loss of 30% of staff
-
Sanofi latest to reveal Brexit stockpiling of drugsCompany says UK job losses inevitable in event of hard or no deal Brexit
-
First migraine prevention drug to hit European marketEuropean Commission green lights Novartis’ Aimovig
-
Alnylam’s amyloidosis drug heads latest crop of CHMP approvalsThree new biosimilars also gets the green light
-
Bluebird’s first gene therapy gets European fast trackFor once, Europe set for approval and launch ahead of US
Latest regulatory appointments
-
Professor Carole Longson moves from NICE to the ABPIShe joins the UK pharma body as its chief scientific officer
-
MedTech Europe appoints new board of directors
Chair of the board Michelle Brennan is among those newly elected
-
Greg Perry joins IFPMA as assistant director generalWill move to the global industry body from the Medicines Patent Pool
-
AVEO appoints Nikhil Mehta as its senior VP, regulatory and quality assurance
He joins the biopharma from Tang Capital Management
-
IFPMA names new communications director
Helen Gallagher joins the association from Ferring Pharmaceuticals
Featured jobs
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Account Director or Senior Account Director
-
Salary TBC
-
Senior Medical Writer
-
Great salary and bebefits
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Senior Account Manager / Account Director
-
Great salary and bebefits
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Senior Project Manager - Medical Writing
-
Great salary and bebefits
- Multi-Channel Account Managers - Road / Homebased – Full or Part...
-
starting from £32, 500
-
Scientific Director
-
Great salary and bebefits
-
Senior Medical Writer
-
Great salary and benefits
Subscribe to our email news alerts
- Regeneron and Teva close gap on rivals with NGF pain drug
- Burson Cohn & Wolfe acquires Hirshorn Zuckerman
- Pfizer signs mRNA flu vaccine deal with BioNTech
- Daily Brief: Summit's $12m lifeline, Biohaven's speech anxiety pill, Crescendo's Humabody progress
- US insurers can peg access to ICER value reviews
- Healthcare Comms appointments
PMHub
Conversis
Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...
Latest intelligence
- If you’re not thinking segmentation, you’re not thinking
- Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
- Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
- The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
- Londonvelophobia (fear of cycling in London) – debunked
- ...
Quick links
Infographics
